SYRS Syros Pharmaceuticals, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
SYRS revenue and earnings
- Quarter ended Sep 30, 2024: revenue n/a, net income −$6.40M, EPS -0.16
- Quarter ended Jun 30, 2024: revenue n/a, net income −$23.3M, EPS -0.59
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.71M, EPS -0.10
- Quarter ended Dec 31, 2023: revenue $387K, net income −$64.4M, EPS -2.23
Recent SYRS insider trades
- Dec 2, 2024: Simonian Nancy A sold 37,070 shares ($10.0K)
- Nov 25, 2024: Simonian Nancy A sold 134,713 shares ($36.4K)
- Nov 19, 2024: Quirk Gerald E sold 46,657 shares ($10.3K)
- Nov 18, 2024: Stephens Kristin sold 36,133 shares ($7.95K)
5%+ owners
- Avidity Partners Management LP: 7.6% (Schedule 13G/A, filed Feb 14, 2025)
Are insiders buying or selling SYRS?
No open-market insider buys or sells of Syros Pharmaceuticals, Inc. were reported in the last 12 months.